About this trial
Drug prescriptions are usual during pregnancy however women and their fetuses still remain an orphan population with regard to drugs efficacy and safety clinical studies. Most xenobiotics diffuse through the placenta and some of them can alter fetus development resulting in structural abnormalities, growth or functional deficiencies. The aim of the study is to study the drug transfer using human placenta after delivery.
Eligibility criteria
Qualifiers
pregnant women older than 18 years,
patient with social security or health insurance,
from the 24th week of amenorrhea,
patient who has given her consent,
Disqualifiers
diabetes-like vascular disease,
arterial hypertension,
known prothrombotic pathology, history of venous thrombosis or pulmonary embolism,
maternal serology HIV+, BHV+, CHV+ and syphilis,
Trial design
Treatments tested in this trial
- Placenta perfusion
Treatment groups
Sponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor
URC-CIC Paris Descartes Necker Cochin
Collaborator